ADARx Pharmaceuticals, Inc.
Research ADARx Pharmaceuticals, Inc. (ADRX) on Bullrun: market cap USD 1.88B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerADRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.88B
- Financial periodQ2 2026
- RevenueUSD 746.00K
- Net income-USD 25.76M
- Free cash flow-USD 27.56M
Valuation Snapshot
latest market cap is USD 1.88B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.45M | -USD 73.09M | USD 259.35M | n/a | -0.97 | USD 66.52M | USD 7.74M | -USD 202.26M |
| FY2024 | USD 0 | -USD 46.36M | -USD 49.02M | n/a | -0.62 | USD 14.03M | USD 4.33M | -USD 137.15M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-19 | USD 1.88B | n/a | n/a | n/a |
About ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ADARx Pharmaceuticals, Inc.'s market cap?
ADARx Pharmaceuticals, Inc.'s market capitalization is USD 1.88B.
What does ADARx Pharmaceuticals, Inc. do?
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.